Frequently Asked Questions
Yes. Medicinal cannabis is legal in New Zealand when prescribed by a registered doctor or nurse practitioner. It is treated as an unapproved medicine, meaning it must meet strict quality standards set by Medsafe before it can be dispensed by a pharmacy.
You can book a consultation directly with a specialist clinic or discuss it with your GP. The prescriber will review your medical history and current symptoms to see if you meet the clinical criteria for a prescription.
Research and patient reports suggest that CBD may help manage the gastrointestinal distress and inflammation often referred to as “endo-belly.” Oral formats are typically studied for their effect on mood and systemic inflammation.
If you are looking for endometriosis treatment in New Zealand, the rising of Matariki offers a significant moment to reflect on your current care and set new intentions for your health. Exploring a clinical pathway for medicinal cannabis in NZ involves a structured process with a registered prescriber.
Quick summary: Endometriosis care in New Zealand often involves a multidisciplinary approach focusing on pain management and quality of life. Patients can legally access medicinal cannabis through a consultation with a registered doctor or nurse prescriber. The clinical pathway in NZ is structured around quality-verified medicines, with each patient’s situation considered individually by a registered prescriber.
Medically reviewed by Dr. William Parkyn. https://cannabisclinic.co.nz/dr-william-parkyn/
Medicinal Cannabis Prescription NZ: The Legal Framework
A common question for those seeking help is whether these options are actually legal. In New Zealand, medicinal cannabis is a highly regulated health service under the Medicinal Cannabis Scheme, which is overseen by Medsafe and the Ministry of Health. You do not need a referral from your regular GP to start this process, though keeping them informed is part of good clinical practice.
To receive a medicinal cannabis prescription, you must have a consultation with a registered medical practitioner or nurse practitioner. During this appointment, the clinician reviews your medical history and current situation to discuss whether medicinal cannabis may be appropriate for you. All products prescribed must meet the Minimum Quality Standards set by the New Zealand government to ensure they are consistent and free from contaminants.
Remembrance: Reflecting on the Diagnostic Hurdles
The first pillar of Matariki is remembrance. For many in the endo community, this involves reflecting on the challenges of the past year: the flares that cancelled plans, the “endo-belly” that made work difficult, and the cycles of traditional pharmaceuticals that may have fallen short.
For a long time, the standard of care in New Zealand relied heavily on a “staircase” of interventions. This often starts with NSAIDs like ibuprofen, moving to hormonal contraceptives, and eventually progressing to surgery or opioid-based analgesics like tramadol.¹ While these are vital tools, research shows a significant number of patients experience inconsistent relief or unmanageable side effects.²
Reflecting on these hurdles is not about dwelling on the negative. It is about acknowledging that endometriosis is a complex, multi-systemic condition. It isn’t just a bad period. It involves systemic inflammation, pelvic muscle tension, and often, a sensitised nervous system.³ Recognising these past struggles is the first step in deciding that the next year needs a more structured approach.
Book a consultation to explore your options: https://cannabisclinic.co.nz/book-now/
Celebration: The Strength of Whānau and the Otago Study
The second pillar of Matariki is a celebration of the present. In 2026, we have cause to celebrate a major milestone in local clinical research. The prospective cohort study led by Dr. Claire Henry at the University of Otago has provided the first high-quality, local data on the role of medicinal cannabis for endometriosis-related pain.⁴
| Clinical Outcome (Otago Study 2026) | Baseline Score (out of 10) | 12-Week Score (out of 10) |
|---|---|---|
| Overall Pelvic Pain | 5.4 | 3.7 |
| “Worst” Pain Level | 7.6 | 5.3 |
| Quality of Life (EHP-30) | 68.7 (higher is better) | 37.4 |
This research is worth celebrating because it validates what many patients have been saying for years. It moves the conversation away from anecdotal wellness talk and into a clinical framework. The study also highlights the “substitution effect,” where participants were able to reduce their reliance on more traditional, often heavier, medications.⁵
Setting Health Intentions for the New Year
The final pillar of Matariki is looking forward. Setting a health intention might mean finally asking for a referral or seeking a second opinion. Under updated best-practice guidelines, the emphasis has shifted toward non-invasive diagnosis and whole-person care.⁶ This means you no longer have to wait for a surgical biopsy to start a presumptive treatment plan.
Your Clinical Intentions for 2026:
- Request a Public Referral: If you haven’t seen a specialist in the last year, ask your GP for a referral to a gynaecologist with an interest in chronic pain.
- Build Your Multidisciplinary Team: Effective management involves a team. This might include a pelvic health physiotherapist, a clinical nutritionist, and a specialist medicinal cannabis clinician.
- Map Your Symptoms: Start the year by keeping a detailed log of your pain, sleep, and mood. This “symptom mapping” is an invaluable tool during a consultation.
| Approach | Focus | Primary Goal |
|---|---|---|
| Traditional Cycle | Surgery & Hormones | Physical tissue removal |
| Clinical Pathway | Multidisciplinary & ECS | Functional quality of life |
The Science of Support: The Endocannabinoid System
When we talk about new care pathways, it is important to understand the biological reason they work. Research has confirmed that the female reproductive system has one of the highest concentrations of endocannabinoid receptors in the body.⁷ These receptors (CB1 and CB2) are found in the uterus, the ovaries, and even within the endometriotic lesions themselves.³
When a person lives with chronic inflammation, their body’s natural levels of cannabinoids can become depleted. By discussing medicinal cannabis with a clinical team, you are exploring a way to supplement this system. The goal is to restore balance to a dysregulated system, helping to modulate how pain signals are processed.
Navigating the Clinical Pathway
If your intention for this Matariki is to explore medicinal cannabis, it is important to do so through a legitimate clinical pathway. This is about a supervised titration process, not just “trying a product.”
The approach follows the “start low, go slow” philosophy. This ensures that any care is well-tolerated and fits into your actual life: whether that involves working, parenting, or studying. A typical pathway involves an initial consultation to review your medical history, followed by a month-long trial to see how your body responds to specific ratios.
- Step 1: Initial consultation and medical review.
- Step 2: Personalised titration plan (starting with low-dose CBD oil).
- Step 3: Ongoing monitoring and symptom mapping.
Matariki reminds us that growth requires both looking back and looking ahead. For the endometriosis community in Aotearoa, the 2026 New Year is a time of renewed hope. We are moving into an era of evidence-based, patient-centred care.
If exploring medicinal cannabis is part of your intention for the year ahead, our team is here to support that conversation. You can book a consultation to discuss your options with a registered prescriber.
Explore the clinical process: https://cannabisclinic.co.nz/medicinal-cannabis-prescription-process-nz/
References
- BPAC NZ. Medical management of endometriosis: A step-wise strategy. Best Practice Journal. 2021. https://bpac.org.nz/2021/endometriosis.aspx
- Henry C, et al. Perceived impact of medicinal cannabis on pelvic pain and endometriosis related symptoms in Aotearoa New Zealand: an observational cohort study. BMC Complementary Medicine and Therapies. 2026;26(1):60. https://pmc.ncbi.nlm.nih.gov/articles/PMC12908271/
- Lingegowda H, et al. Targeting the Endocannabinoid System: A Promising Approach to Controlling Endometriosis-Related Pain. Journal of Women’s Health. 2022;31(4):485-492. https://digitalcommons.linfield.edu/cgi/viewcontent.cgi?article=1002&context=nursstud_464
- University of Otago. Medicinal cannabis may offer relief for endometriosis and pelvic pain. 2026. https://www.otago.ac.nz/news/newsroom/medicinal-cannabis-may-offer-relief-for-endometriosis-and-pelvic-pain
- Sinclair J, et al. Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. PLOS ONE. 2021;16(10):e0258940. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0258940
- RANZCOG. Australian Living Evidence Guideline: Endometriosis. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. 2025. https://nzendo.org.nz/endo-news/ranzcog-best-practice-approaches-to-the-management-of-endometriosis-and-pelvic-pain/
- RANZCOG. Australian Living Evidence Guideline: Endometriosis. 2025. https://nzendo.org.nz/endo-news/ranzcog-best-practice-approaches-to-the-management-of-endometriosis-and-pelvic-pain/
- NZ Ministry of Health. Medicinal Cannabis Scheme: Information for patients. 2026. https://www.health.govt.nz/regulation-legislation/medicinal-cannabis/information-patients
Disclaimer: Medicinal cannabis and CBD oil are unapproved medicines in NZ which means that there is no conclusive evidence for their effect, apart from Sativex. Many doctors do not routinely prescribe cannabis medicines. The above article was written for general educational purposes and does not intend to suggest that medicinal cannabis can be used to treat any health condition. Please consult with your healthcare provider.